December 29, 2014 4:33 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Below are the top drugs generic stocks on the NASDAQ in terms of EPS growth forecast for the next five years.
Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) earnings per share growth forecast for the next five years is 70.00%. Sagent Pharmaceuticals' PEG ratio is 0.88.
Evoke Pharma, Inc. (NASDAQ: EVOK) EPS growth forecast for the next five years is 40.00%. Evoke Pharma's trailing-twelve-month EPS is -$1.98.
Akorn, Inc. (NASDAQ: AKRX) EPS growth forecast for the next five years is 33.15%. Akorn's trailing-twelve-month profit margin is 5.10%.
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) earnings per share growth forecast for the next five years is 19.20%. Avanir Pharmaceuticals' trailing-twelve-month revenue is $115 million.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.